Congress moves to expose industry funding of patient advocacy groups
S. 2710 — Open Payments Expansion Act · Filed by Chuck Grassley (R-IA) · 1 cosponsor · Introduced Sep 4, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands the existing 'Open Payments' transparency law (which requires doctors to disclose payments from drug and device makers) to also capture payments manufacturers make to patient advocacy organizations. Starting in 2027, drug and device companies must report all direct and indirect payments to patient groups, including money funneled through third parties. The goal is to shine light on industry funding of advocacy organizations that influence patient opinion and healthcare policy.
Why we flagged it
The bill extends existing Open Payments disclosure requirements (Physician Payments Sunshine Law) to capture previously unreported payments from drug and device manufacturers to patient advocacy organizations. This is a transparency/disclosure mechanism, not a substantive regulatory change.
What the text implies
- Expands the definition of 'covered payments' to include indirect transfers through third parties, potentially capturing funding flows that manufacturers currently obscure via intermediaries—this may reveal undisclosed influence relationships between industry and patient advocacy groups.
- The March 31, 2027 implementation date and 90-day annual reporting cadence create a new administrative burden on manufacturers and GPOs, but also establish a public record of industry funding to advocacy organizations that currently operate with minimal disclosure.
The full analysis lists 5 implications of this text.
Who stands to gain
transparency/compliance software vendors; healthcare data analytics firms; patient advocacy organizations (via increased visibility and potential donor interest)